Menu
Not yet recruiting NCT07109102

Long-Term Benefits of Eccentric Cycling Exercise in Patients With Type 2 Diabetes Mellitus

No phase Interventional Type 2 Diabetes Mellitus (T2DM)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Moderate-intensity eccentric cycling, High-intensity eccentric cycling, Moderate-intensity concentric cycling.
Who it may be relevant to
Registry conditions: Type 2 Diabetes Mellitus (T2DM). Basic parameters: 30 years — 60 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Malaysia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Exploring Long-Term Benefits of Eccentric Cycling Exercise on Physiological Responses, Exercise Capacity, and Quality of Life in Patients With Type 2 Diabetes Mellitus

Overview

The goal of this interventional study is to evaluate the long-term benefits of eccentric (ECC) cycling exercise on physiological responses, exercise capacity, and quality of life (QoL) in patients with type 2 diabetes mellitus (T2DM). The main questions it aims to answer are: * What are the effects of ECC cycling compared to concentric (CON) cycling on physiological responses, exercise capacity, and QoL in patients with T2DM? * What are the differential effects of moderate- and high-intensity ECC cycling compared to CON cycling on physiological responses, exercise capacity, and QoL in patients with T2DM? Researchers will compare moderate- and high-intensity ECC cycling to CON cycling (conventional cycling) to see if ECC cycling can be a viable alternative or complement to existing exercise protocols for managing T2DM. Participants will: * Undergo pre-, mid-, and post-intervention assessment * Perform either moderate- or high-intensity ECC cycling or moderate intensity CON cycling according to group randomisation by the researcher. * Start with two familiarisation sessions prior to the actual cycling training. * Perform cycling exercise twice per week for 10 weeks.

Interventions

  • Other Moderate-intensity eccentric cycling
    * This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer. * The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test. * The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO).
  • Other High-intensity eccentric cycling
    * This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer. * The intensity will start at 80% of the peak power output (PPO) of the incremental concentric cycling test. * The intensity will progressively increase by 5% of PPO every 2 weeks (80%-100% PPO).
  • Other Moderate-intensity concentric cycling
    * This group will perform concentric cycling exercise twice per week for ten weeks using the Lode Excalibur sport ergometer. * The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test. * The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO).

Primary outcome measures

  • Glycated haemoglobin (HbA1C) [Time frame: Baseline and post-intervention at 10 weeks]
  • Lipid profile [Time frame: Baseline and post-intervention at 10 weeks]
  • Maximal voluntary contraction (MVC) [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks).]
  • Exercise capacity [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
  • 13-item Revised Version of Diabetes Quality of Life (RV-DQOL13) [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
  • Short Form-12 (SF-12) health survey [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
Secondary outcome measures (9)
  • Electromyography (EMG) for muscle activity assessment [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
  • Blood pressure [Time frame: Baseline and up to 10 weeks]
  • Heart rate [Time frame: Baseline and up to 10 weeks]
  • Borg Category-Ratio scale (Borg CR-10) [Time frame: Every cycling training session from week 1 to week 10]
  • Body weight [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
  • Height [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
  • Body mass index (BMI) [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
  • Body circumference [Time frame: Baseline, mid-intervention (6 weeks), and post-intervention (10 weeks)]
  • The short version of the physical activity enjoyment scale (PACES-S) [Time frame: Mid-intervention (6 weeks), and post-intervention (10 weeks)]

Eligibility criteria

Inclusion criteria

  • Male diagnosed with T2DM
  • Age 30 - 60 years old
  • Height ≥155cm (To ensure proper ergonomics, comfort and safety during cycling)
  • HbA1C level between 6-8%
  • No resistance exercise for ≤ 3 months before participating in the current study.
  • Physical inactivity (moderate to vigorous exercise ≤60 minutes weekly based on International Physical Activity Questionnaires-Short Form (IPAQ-SF))

Exclusion criteria

  • Acute illness or any foot ulcer, diabetic ulcer, retinopathy, kidney, musculoskeletal, cardiovascular, or neurological disorder that could impair exercise performance or pose a risk to participants during exercise.
  • Insulin injection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

Malaysia · 1 center
  • Cardio and Muscle Function Laboratory, Pusat Perubatan USM Bertam — Kepala Batas

Publications

  • Ansari M, Hardcastle S, Myers S, Williams AD. The Health and Functional Benefits of Eccentric versus Concentric Exercise Training: A Systematic Review and Meta-Analysis. J Sports Sci Med. 2023 Jun 1;22(2):288-309. doi: 10.52082/jssm.2023.288. eCollection 2023 Jun. PMID 37293426
  • Borot L, Pageaux B, Laroche D, Vergotte G, Lepers R, Perrey S. Eccentric cycling involves greater mental demand and cortical activation of the frontoparietal network. Scand J Med Sci Sports. 2024 Jan;34(1):e14517. doi: 10.1111/sms.14517. Epub 2023 Oct 9. PMID 37814520
  • Penailillo L, Blazevich AJ, Nosaka K. Factors contributing to lower metabolic demand of eccentric compared with concentric cycling. J Appl Physiol (1985). 2017 Oct 1;123(4):884-893. doi: 10.1152/japplphysiol.00536.2016. Epub 2017 Jun 29. PMID 28663378
  • Hoppeler H. Moderate Load Eccentric Exercise; A Distinct Novel Training Modality. Front Physiol. 2016 Nov 16;7:483. doi: 10.3389/fphys.2016.00483. eCollection 2016. PMID 27899894
  • Marcus RL, Lastayo PC, Dibble LE, Hill L, McClain DA. Increased strength and physical performance with eccentric training in women with impaired glucose tolerance: a pilot study. J Womens Health (Larchmt). 2009 Feb;18(2):253-60. doi: 10.1089/jwh.2007.0669. PMID 19183097
  • Clos P, Laroche D, Stapley PJ, Lepers R. Neuromuscular and Perceptual Responses to Sub-Maximal Eccentric Cycling. Front Physiol. 2019 Mar 28;10:354. doi: 10.3389/fphys.2019.00354. eCollection 2019. PMID 30984032
  • Penailillo L, Blazevich A, Numazawa H, Nosaka K. Metabolic and muscle damage profiles of concentric versus repeated eccentric cycling. Med Sci Sports Exerc. 2013 Sep;45(9):1773-81. doi: 10.1249/MSS.0b013e31828f8a73. PMID 23475167
  • LaStayo P, Marcus R, Dibble L, Frajacomo F, Lindstedt S. Eccentric exercise in rehabilitation: safety, feasibility, and application. J Appl Physiol (1985). 2014 Jun 1;116(11):1426-34. doi: 10.1152/japplphysiol.00008.2013. Epub 2013 Jul 3. PMID 23823152

Identifiers

NCT: NCT07109102 · USM/JEPeM/PP/25030323

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗